V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation.
Using very specific vasopressin (VP) analogues, the human platelet VP receptor was characterized as a V1a rather than a V1b receptor, on the basis of the effect of the analogues on shape-change and aggregation. The platelet VP binding sites appeared to be subject to homologous down-regulation by plasma VP, in view of the inverse correlation found between the maximal capacity of binding of tritiated VP to platelets and the immunoreactive VP concentration in poor platelet plasma from the same individual. Aggregating effect of VP on human platelets was potentiated by both ADP and epinephrine. In addition, VP was able to release serotonin from human platelets, but only at high concentration.
D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000328:Adult; D001127:Arginine Vasopressin / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D001792:Blood Platelets / Q000166:cytology / Q000648:ultrastructure*; D004837:Epinephrine / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011945:Receptors, Angiotensin / Q000187:drug effects* / Q000502:physiology; D017483:Receptors, Vasopressin; D012701:Serotonin / Q000097:blood; D013379:Substrate Specificity; D014667:Vasopressins / Q000097:blood / Q000378:metabolism
D011945:Receptors, Angiotensin; D017483:Receptors, Vasopressin; D014667:Vasopressins; D001127:Arginine Vasopressin; D012701:Serotonin; D000244:Adenosine Diphosphate; D004837:Epinephrine